Skip to main content

Table 1 Patient demographic and clinical characteristics

From: Clinical utility of cerebrospinal fluid-derived circular RNAs in lung adenocarcinoma patients with brain metastases

Character

N (%)

Total N = 21

Age at baseline, years

 Median

55

 Range

39–74

Sex

 Male

9 (43%)

Smoking status

 Current smoker

1 (5%)

 Former smoker

5 (24%)

 Never smoker

15 (71%)

Activating mutation

 EGFR mut

17(81%)

 ALK rearrangement

3 (14%)

 KRAS mut

1 (5%)

LMC

 Yes*

5 (24%)

Baseline PS

 0

1 (5%)

 1

19 (90%)

 2

1 (5%)

Treatment received

 TKI**

9 (43%)

 TKI + SRS of BM

3 (14%)

 TKI + resection of BM

1 (5%)

 TKI + bev

1 (5%)

Chemotherapy

3 (14%)

 Pem + CBP + Bev

1 (5%)

 Pem + Bev

1 (5%)

 Paclitaxel + CBP + Bev

1 (5%)

WBI + BSC

2 (10%)

BSC

2 (10%)

  1. EGFR epidermal growth factor receptor, ALK anaplastic lymphoma kinase, KRAS Kirsten rat sarcoma viral oncogene homologue, mut mutant, BM brain metastasis, LMC leptomeningeal carcinomatosis, PS performance status, TKI tyrosine kinase inhibitor, SRS stereotactic radiosurgery, Pem pemetrexed, CBP carboplatin, Bev bevacizumab, WBI whole brain irradiation, BSC best support care
  2. *Patient was considered to have LMC should had at least one positive result of cerebrospinal fluid (CSF) cytology and brain magnetic resonance imaging (MRI). Three patients were diagnosed with LMC by CSF cytology, brain MRI, accompanied by neurological symptoms, which included headache, confusion, cognitive impairment and psychiatric disorders. The other two patients were diagnosed with LMC by brain MRI without symptom or CSF cytology
  3. **Details of TKI regimens are shown in Additional file 5: Table S5